HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Feb. 2, 2018 (HealthDay News) -- An outbreak of multidrug-resistant malaria in southeast Asia likely stems from two mutations of the malaria-causing parasite that combined a decade ago, according to new research.
The parasite and mutations, carried by mosquitoes, spread rapidly in the region for five years before the malaria outbreak became apparent, the researchers said.
Now, to reduce the risk of the parasite becoming untreatable, the investigators urge malaria control programs to closely monitor genetic mutations in the mosquito-borne parasite.
The research was published Feb. 1 in The Lancet Infectious Diseases.
Typically, malaria treatment involves a combination of drugs -- a fast-acting one (called artemisinin) and a longer-acting one. This is to ensure that all parasites are killed and to prevent the emergence of drug resistance, the study authors explained.
But in 2008, malaria-causing Plasmodium falciparum parasites started to become resistant to artemisinin in western Cambodia. That resistance now has spread to other parts of Cambodia, as well as to Laos, Myanmar, Thailand and Vietnam, according to the report.
Since 2013, there has been a rapid increase in the rates of complete treatment failure in patients receiving a drug combination of dihydroartemisinin and piperaquine in Cambodia, northeast Thailand, and Vietnam, the researchers said.
"Malaria policy makers now face a dilemma," the study's lead researcher, Roberto Amato, said in a journal news release. He's a population geneticist with the Wellcome Sanger Institute in England.
"On one hand, malaria remains treatable and its prevalence has been reduced to low enough levels to aim to eliminate the disease in Cambodia and neighboring countries. However, the situation is fragile, and it is unclear how the parasite population will evolve in response to new interventions," he said.
"While it would be catastrophic if resistance developed in the same way for the last remaining anti-malarial drugs, it is now possible to conduct genetic surveillance of malaria cases, allowing researchers to respond as soon as possible to changes in the parasite population," Amato said.
"It is important that we embrace these technologies so that major outbreaks of resistance do not go unnoticed in the future, and to reduce the risk of a global health emergency," he added.
The U.S. Centers for Disease Control and Prevention has more on malaria.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 28, 2022